P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

Podobne zapisy

• P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES
  od: Aurore Perrot, i wsp.
  Wydane: (2023-08-01)
• P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
  od: Philippe Moreau, i wsp.
  Wydane: (2023-08-01)
• Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
  od: Tom Martin, i wsp.
  Wydane: (2022-06-01)
• P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
  od: Thierry Facon, i wsp.
  Wydane: (2023-08-01)
• LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
  od: E Crusoe, i wsp.
  Wydane: (2023-10-01)